Biologics Market Size, Share, Industry & Opportunities 2031

Report Description

 Biologics Market Outlook

The Biologics Market size was USD 461.74 Billion in 2022 and is likely to reach USD 1.11 Trillion by 2031, expanding at a CAGR of 10.3% during 2023–2031. The growth of the market is attributed to the advancement in the research activities & diagnostics, high number of product approvals, and great prevalence of diseases worldwide.

Biologics are genetically engineered proteins, which are derivative of human genes. As per the US Food and Drug Administration (FDA), biologics can be prepared from proteins, sugars, or maybe living entities such as cells and tissues, nucleic acids or complex combinations of these substances.

Get Free Sample Report

The majority of biologics are complex combinations that are not easy to identified or characterize and are susceptible to microbial infections as well as heat sensitive. The biologic products are obtained from several natural sources such as humans, microorganisms, or animals. These products comprise of allergenic, vaccines, somatic cells, blood and blood components, tissues, gene therapy, and recombinant therapeutic proteins.

The advanced and complex biotechnology techniques are used to manufacture biologics. Different products of biologics are vaccines, monoclonal antibodies, recombinant hormones/proteins, cellular-based biologics, gene-based biologics, and others. Applications of the biologics are cancer, autoimmune diseases, rare diseases, infectious diseases, and others.

As per the reports of 2018 by the World Health Organization (WHO), chronic diseases was responsible for more than 41 million people death every year globally. Cardiovascular diseases is responsible for high number of chronic disease deaths that is 17.9 million people yearly, which is led by cancers with 9 million, respiratory diseases with 3.9 million death, and diabetes is with 1.6 million deaths.

These four diseases are responsible for around 80% of all chronic disorder related deaths. Physical inactivity, tobacco use, unhealthy diets, and alcohol consumption are some of them major factors for increasing the risk of mortality from non-communicable diseases.? In addition, the growing geriatric population is much at risk to chronic diseases, which supports the growth of the biologics market.

The COVID-19 pandemic outbreak proved to be beneficial for the biologics market since there has been a great demand for biologics due to the pandemic. For example, the collaboration of China-based CanSino Biologics and National Research Council of Canada in May 2020, for the clinical development of a COVID-19 vaccine in Canada, has boosted the market for more research activities of the COVID-19 vaccines.

This collaboration was focused on the development of vaccine, called as Ad5-nCoV, which is an adenovirus type 5 vector-based vaccine. Thus, this shows that wide research and development activities on biologics for the prevention and treatment of COVID-19 are taking place around the world.

Market Trends, Drivers, Restraints, and Opportunities

• Advancements in the manufacturing capabilities of the companies for biological products are estimated to push the biopharmaceutical production capacity. This is a major driver of the biologics market.
• Rising interest of pharmaceutical firms towards massive development of biologics and increasing investments of the companies are propelling the market growth.
• High research and development activities in the field and strong pipeline of products are projected to support the market growth in the coming years.
• Biologics are extremely susceptible to light, heat conditions, and need proper refrigeration, which results in non-consistent quality available around the globe. This is proving to be a key restraining factor of the market growth.
• High disease prevalence, increased focus of major players on biologics as well as governments’ initiatives, and extensive research activities are creating huge opportunities of the market expansion during the forecast period.

Scope of  Biologics Market Report

The report on the global biologics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Biologics Market Segment Insights

Microbial segment is expected to grow at a rapid pace

Based on sources, the global biologics market is divided into microbial, mammalian, and others. The microbial segment is expected to grow at a rapid pace in the coming years due to the high number of drugs developed by the use of microbial products. Escherichia Coli and yeast are the most used microbes in this segment. Products manufactured through these systems are granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, recombinant insulin, and recombinant interferon.

Meanwhile, the mammalian segment is expected to register at a fast growth pace in the coming years due to the high demand for mammals in the development of biologics product. Moreover, the rising research and development activities in the segment is projected to drive the overall market growth during the forecast period.

Get Free Sample Report

Monoclonal antibodies segment is projected to expand at a considerable CAGR

On the basis of products, the market is divided into monoclonal antibodies (MABs), vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others. The MABs segment is further classified on the basis of application and types. The application segment includes diagnostics, therapeutics, protein purification, and others; while the diagnostics segment consists of biochemical analysis and diagnostic imaging.

The therapeutics segment is further bifurcated into direct MAB agents and targeting MAB agents. On the basis of types, it is divided into murine, chimeric, humanized, human, and others.

The monoclonal antibodies segment is projected to expand at a considerable CAGR during the forecast period attributed to the high use of drugs in several areas for disease therapeutics. MABs works on unhealthy cells without causing troubles to healthy body cells. These drugs are used in treatment of autoimmune diseases, cancer management, and rheumatoid arthritis. Meanwhile, the vaccines segment is anticipated to grow substantially in the near future due to high investments, extensive R&D activities, and increasing demand for vaccines.

Oncology segment is estimated to hold a major share of the market

Based on diseases, the global biologics market is segregated into oncology, infectious diseases, immunological disorders, cardiovascular disorders, haematological disorders, and others. The oncology segment is estimated to hold a major share of the market during the projected period as the growing prevalence of cancer cases along with high research in the segment. Extensive research is carried out on the antisense therapies and gene therapies for cancer treatment, which is likely to propel the segment growth in the coming years.

In-house manufacturing segment is anticipated to grow at substantial rate

On the basis of manufacturing, the market is bifurcated in to in-house and outsourced. The in-house manufacturing segment is anticipated to grow at substantial rate of the market during the targeted period due to the rising preference of companies to manufacture the products rather than outsourcing it. The companies are investing heavily in the segment and increasing their manufacturing capacity. These factors are helping the segment growth at significant rate but the outsourcing segment is experiencing a moderate growth rate.

 

Get Free Sample Report

North America is anticipated to constitute a major market share

In terms of regions, the global biologics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share during the forecast period. The regional market growth is attributed to high incidences of chronic diseases, high population with alcohol and smoking habits, and rising aging population in the region. The region also has well-developed healthcare services as well as high quality research in the field of biologics, which is expected to fuel the further development of the regional market. Highly skilled professionals and technologically advanced equipment are key factors driving the market growth in the region.

Meanwhile, Asia Pacific is a key market destination that hold tremendous opportunities to grow in the coming future as there is high number of the targeted patients. Additionally, large number of research projects and heavy investments are projected to boost the market growth in the region.

Get Free Sample Report